Topical pimecrolimus is rated category C as there have been no adequate studies in pregnant women.

TCIs such as pimecrolimus have a black-box warning from theoretical risks based on high dose systemic calcineurin inhibitor use in post-transplant patients and animal studies.

Some formulations of topical pimecrolimus contain benzyl alcohol and propylene glycol as inactive ingredients, which have been reported to cause serious adverse effects in neonates.s when administered intravenously, and large amounts of propylene glycol administered orally, intravenously, or topically may also result in neonate fatality.